---

---

tags : Phase 3    source : Www.prnewswire.com   

save search

---

Novan Announces Publication of Positive Results from Pivotal Phase 3 Study of Berdazimer Gel, 10.3% (SB206) in Patients with Molluscum Contagiosum in JAMA Dermatology
Published: 2022-07-13 (Crawled : 16:00) - prnewswire.com
NOVN | $0.0941 -24.84% -32.91% 7.2M |

Health Technology

| -96.24% | O: -2.0% H: 22.45% C: 4.08%
sb206 molluscum positive results publication study phase 3

---

Biohaven Enrolls First Patient in Phase 3 Trial of Taldefgrobep alfa in Spinal Muscle Atrophy (SMA)
Published: 2022-07-07 (Crawled : 12:00) - prnewswire.com
BHVN | News 0 d | $39.335 -6.7% 1.2M |

Health Technology

| -71.05% | O: -0.11% H: 0.14% C: -0.17%
trial phase 3

---

Annovis Bio Announces Positive FDA Notice For Buntanetap Phase 3 Clinical Trial In Parkinson's Disease
Published: 2022-07-07 (Crawled : 12:00) - prnewswire.com
ANVS | $10.06 2.13% 70K |

Health Technology

| -25.72% | O: 11.24% H: 7.12% C: 1.69%
fda disease trial positive buntanetap anvs401 posiphen phase 3

---

Jazz Pharmaceuticals Announces Top-line Results from Phase 3 Trial Evaluating Nabiximols Oromucosal Spray in Adult Participants with Multiple Sclerosis Spasticity
Published: 2022-06-28 (Crawled : 12:00) - prnewswire.com
JAZZ | $110.6 1.22% 210K |

Health Technology

| -31.65% | O: -0.78% H: 1.49% C: -0.15%
trial results sclerosis phase 3 topline

---

SIGMA LITHIUM SUBSTANTIALLY INCREASES TOTAL NI 43-101 MINERAL RESOURCE BY ~50% TO 86 MILLION TONNES, ADDING 27 MILLION TONNES OF HIGH-GRADE 1.49% LITHIUM OXIDE IN PHASE 3
Published: 2022-06-22 (Crawled : 14:00) - prnewswire.com
SGML | $13.39 -0.15% 350K |

Mining, Quarrying, and Oil and ...

| -5.94% | O: 1.13% H: 6.83% C: 5.9%
LTUM | $0.0364 230K |

Mining, Quarrying, and Oil and ...

| -81.98% | O: 2.43% H: 0.0% C: -7.65%
lithium phase 3

---

Ionis announces eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)
Published: 2022-06-21 (Crawled : 07:00) - prnewswire.com
IONS | $40.465 -0.85% 260K |

Health Technology

| 18.81% | O: 5.44% H: 0.0% C: 0.0%
eplontersen phase 3

---

Phexxi® Prevented 99% of Pregnancies Per Act of Intercourse in a Post Hoc Analysis of Phase 3 AMPOWER Clinical Trial Data
Published: 2022-06-16 (Crawled : 13:00) - prnewswire.com
EVFM | $0.0141 180K |

Health Technology

| -96.69% | O: -1.09% H: 2.41% C: -3.72%
phexxi trial phase 3

---

Biohaven Presents New Migraine Data at 64th Annual Scientific Meeting of the American Headache Society, including First of Its Kind Study for Nurtec® ODT (rimegepant), and Complete Phase 3 Data for Zavegepant Nasal Spray
Published: 2022-06-13 (Crawled : 12:00) - prnewswire.com
BHVN | News 0 d | $39.335 -6.7% 1.2M |

Health Technology

| -70.76% | O: -0.41% H: 0.44% C: 0.14%
nurtec migraine phase 3

---

Endo Executes Agreement With TLC to Commercialize Phase 3 Orthopedic Product for the Treatment of Osteoarthritis Knee Pain
Published: 2022-06-13 (Crawled : 11:00) - prnewswire.com
ENDP | $0.2926 -9.6% |

Health Technology

| -20.96% | O: 5.35% H: 1.26% C: -21.85%
treatment osteoarthritis phase 3

---

Everest Medicines' Licensing Partner Gilead Sciences Announces Positive Results from Phase 3 TROPiCS-02 Study of Trodelvy® in Heavily Pre-treated HR+/HER2- Metastatic Breast Cancer Patients
Published: 2022-06-04 (Crawled : 16:20) - prnewswire.com
GILD | News | $66.33 0.26% 2.8M |

Health Technology

| Email alert Add to watchlist
cs-02 trodelvy sciences positive results cancer breast cancer phase 3 her2- her2 metastatic breast cancer

---

Phase 3 SHINE Results Show IMBRUVICA® (ibrutinib)-Based Combination Regimen Significantly Reduced the Risk of Disease Progression or Death in Older Patients with Newly Diagnosed Mantle Cell Lymphoma
Published: 2022-06-03 (Crawled : 14:00) - prnewswire.com
FNCTF | News | $11.0354 320 |

Communications

| -10.28% | O: -2.68% H: 0.0% C: 0.0%
JNJ | News | $147.17 0.98% 3.2M |

Health Technology

| -18.44% | O: -0.37% H: 0.0% C: 0.0%
imbruvica risk disease results order phase 3

---

AbbVie Presents Positive Results from Phase 3 SELECT-AXIS 2 Trials of Upadacitinib (RINVOQ®) in Patients with Axial Spondyloarthritis at EULAR 2022
Published: 2022-06-01 (Crawled : 15:00) - prnewswire.com
ABBV | News | $166.43 1.08% 2M |

Health Technology

| 11.4% | O: -0.55% H: 0.0% C: 0.0%
rinvoq trials positive results phase 3

---

The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Risankizumab (SKYRIZI®) in Crohn's Disease
Published: 2022-05-27 (Crawled : 08:00) - prnewswire.com
ABBV | News | $166.43 1.08% 2M |

Health Technology

| 8.56% | O: -1.98% H: 0.0% C: 0.0%
skyrizi disease lancet risankizumab results phase 3

---

The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ®) in Ulcerative Colitis
Published: 2022-05-27 (Crawled : 08:00) - prnewswire.com
ABBV | News | $166.43 1.08% 2M |

Health Technology

| 8.56% | O: -1.98% H: 0.0% C: 0.0%
rinvoq lancet results phase 3 ulcerative colitis

---

SIGMA LITHIUM ANNOUNCES FILING TECHNICAL REPORT WITH OUTSTANDING ECONOMIC RESULTS OF THE INTEGRATED PHASE 1 & 2 PROJECTED PRODUCTION: AFTER-TAX NPV OF US$5.1 BILLION & AVERAGE ANNUAL FREE CASH FLOW OF US$595 MILLION; CONTINUES EVALUATING PHASE 3
Published: 2022-05-26 (Crawled : 14:00) - prnewswire.com
SGML | $13.39 -0.15% 350K |

Mining, Quarrying, and Oil and ...

| -2.95% | O: 1.17% H: 13.13% C: 10.06%
LTUM | $0.0364 230K |

Mining, Quarrying, and Oil and ...

| -83.19% | O: 0.88% H: 3.54% C: 3.46%
report lithium flow results phase 1 phase 3

---

Fifty Percent of Patients with Ulcerative Colitis Treated with Mirikizumab Achieved Clinical Remission at One Year in Lilly's Pivotal Phase 3 Study
Published: 2022-05-24 (Crawled : 08:00) - prnewswire.com
LLY | $727.48 -2.48% 2M |

Health Technology

| 150.39% | O: 1.29% H: 1.3% C: 0.74%
year one phase 3 ulcerative colitis

---

VISEN Pharmaceuticals Announces Top-line Results of Phase 3 Trial of Once-Weekly Lonapegsomatropin, Demonstrating Superior Efficacy, Comparable Safety and Tolerability to Daily Growth Hormone
Published: 2022-05-23 (Crawled : 08:00) - prnewswire.com
ASND | $138.68 -1.57% 91K |

Health Technology

| 53.49% | O: 4.07% H: 2.7% C: 1.55%
trial results growth hormone phase 3 topline

---

Evkeeza® (evinacumab) Phase 3 Trial Demonstrates 48% LDL-C Reduction in Children with Ultra-rare Form of High Cholesterol
Published: 2022-05-21 (Crawled : 12:20) - prnewswire.com
SNYNF | News | $92.7 600K |

Health Technology

| Email alert Add to watchlist
SNY | News | $46.545 2.55% 2.3M |

Health Technology

| Email alert Add to watchlist
REGN | $894.71 0.08% 180K |

Health Technology

| Email alert Add to watchlist
TEVJF | $12.37 -24.22% 380 |

Health Technology

| Email alert Add to watchlist
evkeeza children cholesterol trial phase 3 rare

---

Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology
Published: 2022-05-20 (Crawled : 08:00) - prnewswire.com
RDUS | $18.59 0.36% 77K |

Health Technology

| 212.35% | O: -2.67% H: 0.0% C: 0.0%
elacestrant trial publication group phase 3 elascestrant

---

Citius Pharmaceuticals to Accelerate Phase 3 Mino-Lok Trial by Expanding Trial Sites Internationally
Published: 2022-05-06 (Crawled : 14:00) - prnewswire.com
CTXR | $0.75 -6.89% 1.2M |

Health Technology

| -22.96% | O: 3.78% H: 13.37% C: 2.97%
trial phase 3

---

Gainers vs Losers

72%

28%

Top 10 Gainers

AGBA | News | $1.27 217.5% 120M |

Finance

EGOX | $0.054 50.0% 290M |

RWOD | $10.52 31.56% 5.9M |

n/a

ZCMD | $1.905 31.38% 30M |

Commercial Services

NVFY | $2.71 28.44% 31M |

Consumer Durables

MRDB 4 | $0.536 27.65% 2M |

n/a

BSFC | $0.0822 27.64% 75M |

Manufacturing

TPET | $0.4121 25.68% 45M |

n/a

INDO | $5.1 25.0% 15M |

Energy Minerals

CHRO | $1.53 24.9% 100K |

n/a

---

Your saved searches

---